The review concludes that ANSTO’s price for services for, and behalf of, government, their pricing policies in regards to the commercial sale of radiopharmaceuticals, and access arrangements to ANSTO’s two major facilities are all appropriate. The Government recognises ANSTO’s role in training, and has decided that there will be no further cuts in ANSTO’s research activities from current levels.
The Government has decided that ANSTO will be funded to maintain its assets according to best practice to ensure they reach their design lives, with funding to be provided to address a maintenance backlog. Increased funding for maintenance in 2001-02 and subsequent years will be allocated through Additional Estimates later in 2001. Increased depreciation funding, based on revalued asset balances arising from an asset revaluation exercise undertaken during the pricing review, will be provided to ANSTO in accordance with the principles of accrual accounting.
